Antimicrobial activity and mechanistic insights of AMP-17 against drug-resistant Pseudomonas aeruginosa and its efficacy in wound infection management
Abstract
Introduction Chronic wound infections caused by drug-resistant bacteria have emerged as a global health challenge, affecting millions of patients annually and imposing a substantial economic and societal burden. However, current therapeutic approaches exhibit limited efficacy in treating drug-resistant wound infections, highlighting an urgent need for novel treatment strategies. Our previous studies have demonstrated that the Musca domestica antimicrobial peptide-17 (AMP-17) exhibits potent antibacterial activity, suggesting its potential as a promising anti-infective agent. Building on these findings, the present study isolated clinically relevant drug-resistant Pseudomonas aeruginosa (P. aeruginosa) strains and employed a combination of in vitro and in vivo experiments to systematically evaluate the efficacy of AMP-17 in combating drug-resistant infections and promoting wound healing. Furthermore, we preliminarily investigated the underlying mechanisms involved. Materials and methods MIC/MBC of AMP-17 against drug-resistant P. aeruginosa were determined by microbroth dilution and agar spot assays. Biofilm inhibition/eradication was assessed via crystal violet staining, while swarming motility was tested on semi-solid agar. A murine wound infection model was established to evaluate the in vivo antimicrobial activity of AMP-17, and the levels of relevant cytokines were measured to preliminarily explore its anti-inflammatory mechanisms. Furthermore, the effects of AMP-17 on…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.